Empirical Osimertinib as a Second-Line Treatment Is a Viable Option Following First- and Second-Generation TKI Therapy With Unknown EGFR Status in Treated Non-Small Cell Lung Cancer: A Retrospective Study.

Cancer Med · 2026 · PMC13109614 · PMID 42032945

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

a nonsignificant trendp = 0.054so close (0.05 < p ≤ 0.1)

Demographics, smoking status, and tumor size were broadly comparable across groups; EGFR subtype distribution showed a nonsignificant trend ( p = 0.054).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.